Breaking News Instant updates and real-time market news.

A

Agilent

$66.26

-0.04 (-0.06%)

, HZNP

Horizon Pharma

$17.44

(0.00%)

04:55
06/14/18
06/14
04:55
06/14/18
04:55

Goldman to hold a conference

Global Healthcare Conference will be held in Rancho Palos Verdes, CA on June 12-14.

A

Agilent

$66.26

-0.04 (-0.06%)

HZNP

Horizon Pharma

$17.44

(0.00%)

ALXN

Alexion

$118.24

0.68 (0.58%)

BGNE

BeiGene

$176.34

-22.25 (-11.20%)

AMGN

Amgen

$183.64

-1.47 (-0.79%)

QGEN

Qiagen

$37.49

0.3 (0.81%)

HALO

Halozyme

$19.12

0.12 (0.63%)

FGEN

FibroGen

$59.30

1.1 (1.89%)

FOLD

Amicus

$16.06

0.14 (0.88%)

MNK

Mallinckrodt

$18.93

-0.15 (-0.79%)

ABBV

AbbVie

$97.58

-1.36 (-1.37%)

REGN

Regeneron

$308.30

-1.42 (-0.46%)

ALGN

Align Technology

$363.62

9.36 (2.64%)

SAGE

Sage Therapeutics

$169.74

-6.21 (-3.53%)

INSP

Inspire Medical

$34.52

1.48 (4.48%)

ILMN

Illumina

$287.10

-4.96 (-1.70%)

JNJ

Johnson & Johnson

$122.65

0.11 (0.09%)

HUM

Humana

$306.15

0.2 (0.07%)

  • 14

    Jun

  • 14

    Jun

  • 19

    Jun

  • 20

    Jun

  • 11

    Aug

  • 13

    Aug

  • 22

    Aug

  • 12

    Sep

  • 20

    Oct

  • 28

    Oct

A Agilent
$66.26

-0.04 (-0.06%)

05/15/18
JEFF
05/15/18
NO CHANGE
Target $80
JEFF
Buy
Agilent pullback a buying opportunity, says Jefferies
Jefferies analyst Brandon Couillard recommends using the post-earnings pullback in shares of Agilent Technologies as a buying opportunity. Guidance was maintained, despite dilution from Lasergen, and does not yet capture accretion from the pending AATI deal, Couillard tells investors in a research note. He sees no reason to alter his positive thesis and keeps a Buy rating on Agilent with a slightly reduced price target of $80.
06/08/18
BARD
06/08/18
NO CHANGE
Target $77
BARD
Outperform
Agilent recent weakness a buying opportunity, says Baird
Baird analyst Catherine Ramsey Schulte attended Agilent's analyst day and said her positive outlook on the company remains unchanged. She continues to expect strong core growth and margin expansion to help drive above market performance over the next several years. Schulte said she would use recent weakness as a buying opportunity and reiterated her Outperform rating and $77 price target on Agilent shares.
05/15/18
COWN
05/15/18
UPGRADE
COWN
Outperform
Agilent upgraded to Outperform from Market Perform at Cowen
05/15/18
BARD
05/15/18
NO CHANGE
Target $77
BARD
Outperform
Agilent core growth slowing, but underlying business healthy, says Baird
Baird analyst Catherine Ramsey Schulte said Agilent's Q2 growth hit the guidance midpoint, but fell short of expectations due to unforeseen headwinds in China and ICP/MS shipment timing. She noted management remains bullish on end-market outlooks and she still believes they are being conservative with guidance. Although the company's core growth is slowing, she said the underlying business is healthy. Schulte reiterated her Outperform rating and lowered her price target to $77 from $78 on Agilent shares.
HZNP Horizon Pharma
$17.44

(0.00%)

03/01/18
UBSW
03/01/18
NO CHANGE
Target $20
UBSW
Buy
Horizon Pharma one of best profiles in specialty pharma, says UBS
UBS analyst Marc Goodman said Horizon Pharma has one of the best profiles in specialty pharma given its high single-digit to low double-digit sales growth to drive at least low double-digit EBITDA through 2022. Goodman reiterated his Buy rating and $20 price target on Horizon Pharma shares.
03/15/18
CANT
03/15/18
NO CHANGE
Target $17
CANT
Overweight
Physicians divided on adoption of Horizon's Krystexxa, says Cantor Fitzgerald
Since Horizon Pharma guided to a 50% year-over-year increase in Krystexxa sales in 2018 and peak sales of $750M, there has been "considerable debate as to whether or not the company can meet these high expectations," Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After hosting calls with four rheumatologists that treat a large number of gout patients, the analyst says that while physicians believe Krystexxa is the safest and most-efficacious gout drug, they were not all convinced they would switch their patients over to Krystexxa. Chen sees division over Krystexxa adoption but keeps an Overweight rating on Horizon Pharma with a $17 price target.
04/11/18
MZHO
04/11/18
NO CHANGE
Target $18
MZHO
Buy
Selecta drug not imminent threat to Horizon Pharma, says Mizuho
Mizuho analyst Irina Koffler says competitor Selecta Biosciences (SELB) released "directionally positive," but early, data on a potential competitive product to Horizon Pharma's key orphan drug Krystexxa. The analyst does not view Selecta's SEL-212 as an imminent threat to Horizon. She reiterates a Buy rating on Horizon with an $18 price target.
04/16/18
CANT
04/16/18
NO CHANGE
Target $17
CANT
Overweight
Cantor positive on Horizon Pharma after speaking to rheumatologists
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Horizon Pharma with a $17 price target after holding a conference call with two rheumatologists to discuss the market opportunity for Krystexxa. Both doctors agreed that Krystexxa is a very good drug and works best for a small group of refractory patients, which is all Horizon needs to meet or beat its peak sales forecast, Chen tells investors in a research note. The analyst believes there has been considerable debate as to whether the company can meet its forecasts.
ALXN Alexion
$118.24

0.68 (0.58%)

05/08/18
EVER
05/08/18
NO CHANGE
Target $150
EVER
Outperform
Alexion EU patent not 'a need to have,' says Evercore ISI
Evercore ISI analyst Josh Schimmer notes Alexion is trading lower after an announcement that the European Patent Office rejected a new composition of matter patent for Soliris which could extended to 2027. The analyst points out that this patent was never part of his investment thesis, as he views it more as a "nice to have" rather than a "need to have" for success given many additional barriers to entry including label expansions and raising the bar through Q8W 1210 IV and ultimately s.c. dosing. Schimmer reiterates an Outperform rating and $150 price target on the shares. In afternoon trading, shares of Alexion have dropped over 4% to $113.23.
06/05/18
FBCO
06/05/18
NO CHANGE
Target $154
FBCO
Outperform
Alexion price target raised to $154 from $149 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Alexion to $154 from $149 saying the resolution of overhangs on the shares supports upside, namely if a global 1210 switch strategy is viable given Soliris EU IP uncertainty and what will drive long-term growth for Alexion. The analyst expects partial or full resolution of the first overhang as investors recognize that biosimilar risk may largely be limited to the PNH indication, and lackluster competitive C5 data and probable biosimilar pushouts suggest bearish timeline assumptions are low risk, likely allowing ample time to convert the market to 1210 from Soliris. Auster reiterates an Outperform rating on the shares.
05/08/18
PIPR
05/08/18
NO CHANGE
Target $170
PIPR
Overweight
Alexion should be bought on weakness, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says he would be a buyer of Alexion's shares on weakness today as he thinks the market's reaction to what really amounts to "nothing more than a procedural update" from the EPO is "wholly misplaced." The analyst reminds investors that the Soliris composition of matter patent in question already was subject to a first office action rejection in November of last year. This recent news reflects a continuation of that back and forth, and the real revelation on this does not occur till the oral hearing next February, he adds. Raymond reiterates an Overweight rating and $170 price target on the shares.
05/08/18
JEFF
05/08/18
NO CHANGE
JEFF
Hold
Alexion CoM patent for Soliris rejected by European regulator, says Jefferies
Jefferies analyst Eun Yang reported that the European Patent Office's Examining Division issued a rejection to Alexion's new Composition of Matter, or CoM, patent application for Soliris. If one is not issued, a potential biosimilar entry is likely in about 2020 in the EU, added Yang, who noted that the company has requested oral proceedings, which are set to take place in February 2019. The analyst has a Hold rating on Alexion.
BGNE BeiGene
$176.34

-22.25 (-11.20%)

04/13/18
PIPR
04/13/18
INITIATION
Target $200
PIPR
Overweight
BeiGene initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren started BeiGene with an Overweight rating and $200 price target. The analyst believes the stock offers "multiple ways to win." His rating is based on the potential for zanubrutinib differentiation and the successful development of tislelizumab and/or pamiparib. The Chinese market has become much more attractive for global drug manufacturers, Van Buren tells investors in a research note.
05/14/18
05/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. General Electric (GE) initiated with a Buy at Gabelli. 2. Western Digital (WDC) initiated with an Overweight at JPMorgan. 3. GrafTech (EAF) initiated with an Overweight at JPMorgan and an Outperform at RBC Capital. 4. Surface Oncology (SURF) initiated with an Outperform at Evercore ISI and Cowen as well as a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
FBCO
05/14/18
INITIATION
FBCO
Outperform
BeiGene initiated with an Outperform at Credit Suisse
05/18/18
MAXM
05/18/18
NO CHANGE
Target $225
MAXM
Buy
BeiGene price target raised to $225 from $200 at Maxim
Maxim analyst Jason McCarthy raised his price target on BeiGene to $225 and kept his Buy rating after the company's announced pivotal study to move into ovarian cancer treatment in China. The analyst notes that as a China-based company, BeiGene has a "distinct advantage" in potentially bringing a PARP inhibitor candidate to that market. McCarthy also points to the China market opportunity, where the majority of 50K ovarian cancer cases are moving to maintenance therapy.
AMGN Amgen
$183.64

-1.47 (-0.79%)

06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
06/05/18
JEFF
06/05/18
NO CHANGE
Target $200
JEFF
Buy
Jefferies thesis on Amgen unchanged after Mylan biosimilar approval
Jefferies analyst Michael Yee says the approval of Mylan's (MYL) Neulasta biosimilar is a headline risk factor for Amgen (AMGN) but does not change his thesis on the latter as consensus already knew a biosimilar was coming. The Street models some Neulasta decline already and Amgen's multi-year low price-to-earnings multiple reflects some of this, Yee tells investors in a research note. He keeps a Buy rating on Amgen shares with a $200 price target.
QGEN Qiagen
$37.49

0.3 (0.81%)

01/22/18
LEHM
01/22/18
NO CHANGE
Target $60
LEHM
Overweight
Quidel price target raised to $60 from $50 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel (QDEL) to $60 from $50 and for Qiagen (QGEN) to $40 from $39 ahead of the companies' Q4 results. The fundamental drivers for the Life Science Tools & Diagnostics group are "on a solid footing" into earnings, Meehan tells investors in a research note. The analyst favors both names with Overweight ratings.
01/03/18
EVER
01/03/18
INITIATION
Target $35
EVER
Outperform
Qiagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Qiagen with an Outperform rating and $35 price target.
01/29/18
GSCO
01/29/18
INITIATION
Target $39
GSCO
Buy
Qiagen initiated with a Buy at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Qiagen with a Buy and $39 price target telling investors it will benefit from a wave of diagnostics product cycles which should lead to MSD-HSD organic growth as HPV headwinds abate in first half 2018.
01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.
HALO Halozyme
$19.12

0.12 (0.63%)

01/24/18
GSCO
01/24/18
INITIATION
Target $20
GSCO
Neutral
Halozyme initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated Halozyme with a Neutral and $20 price target.
01/24/18
DBAB
01/24/18
NO CHANGE
Target $21
DBAB
Buy
Halozyme target raised to $21 after investor meetings at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Halozyme shares to $21 from $19 after hosting investor meetings with management. The meetings offered a "robust reminder" of the strength of the company's dual-pillar strategy, Peters tells investors in a research note. The analyst believes Halozyme's Enhanze platform continues to be underappreciated by investors. He reiterates a Buy rating on the shares.
02/21/18
ADAM
02/21/18
NO CHANGE
Target $21
ADAM
Buy
Halozyme pipeline progress leads to price target increase at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Halozyme to $21 from $19 citing its pipeline progress and steady Enhanze progress. Lee reiterated her Buy rating on Halozyme shares.
05/11/18
LEHM
05/11/18
DOWNGRADE
Target $19
LEHM
Underweight
Halozyme downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Halozyme Therapeutics to Underweight with a $19 price target. The analyst sees limited upside to revenue estimates in 2018 and "high risk" for the company's Phase 3 readout in pancreatic cancer.
FGEN FibroGen
$59.30

1.1 (1.89%)

02/28/18
LEER
02/28/18
NO CHANGE
Target $88
LEER
Outperform
FibroGen price target raised to $88 from $80 at Leerink
Leerink analyst Geoffrey Porges raised his price target for FibroGen to $88 from $80 after the company n reported Q4 financial and operational results, and provided updated later timing for the U.S. roxadustat phase III trials and approval in chronic kidney disease. The analyst reiterates an Outperform rating on the shares.
11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.
05/15/18
MZHO
05/15/18
UPGRADE
Target $61
MZHO
Buy
FibroGen upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded FibroGen to Buy with an unchanged price target of $61. With a "solid" cash position, the company continues to make progress on its research and development pipeline, Yang tells investors in a research note. The analyst expects top-line Phase 3 data from Roxadustat in chronic kidney disease in Q4 and a potential regulatory approval in China is expected by year-end 2018. Yang believes believe FibroGen is likely to gain the first approval in new generation anemia drugs.
FOLD Amicus
$16.06

0.14 (0.88%)

10/04/17
BOFA
10/04/17
NO CHANGE
Target $20
BOFA
Buy
Amicus price target raised to $20 from $15 at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad raised Amicus' price target to $20 from $15 saying the Phase 1/2 trial results of ATB200/AT2221 in Pompe disease were impressive. The analyst thinks the strong data justifies progression into pivotal trials and may result in an accelerated approval path. Ahmad rates Amicus a Buy.
09/15/17
JPMS
09/15/17
NO CHANGE
Target $15
JPMS
Overweight
JPMorgan continues to see upside in Amicus shares
JPMorgan analyst Anupam Rama says Amicus Therapeutics remains one of his top picks, and that he continues to see upside from current share levels, ahead of the upcoming Pompe data readout. The analyst sees a high probability that the Q3 data update will meet or exceed the efficacy benchmarks, leading to increased probability of success/revenue estimates across Street models. His base case, with a 75% probability of success assumption, still provides for 10%-15% upside from current share levels. His "homerun scenario," which is maintaining the 6MWD benefit shown in Q2 or better, has the stock rallying 35%-40%.
04/11/18
JPMS
04/11/18
NO CHANGE
JPMS
Overweight
Amicus risk/reward favorable into regulatory update, says JPMorgan
JPMorgan analyst Anupam Rama notes that a regulatory update for Amicus Therapeutics' Pompe program is expected in Q2. The analyst continues to like the reward/risk profile of the shares going into the update. An accelerated approval path forward is "very much on the table," based on the strength of the Phase 1/2 data, Rama tells investors in a research note. He sees "more win scenarios than lose." The analyst believes Amicus shares can rally 30%-50% should an accelerated approval path forward emerge. Rama keeps an Overweight rating on Amicus with a $19 price target.
05/08/18
JPMS
05/08/18
NO CHANGE
JPMS
Amicus lower on Pompe program commentary, says JPMorgan
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.
MNK Mallinckrodt
$18.93

-0.15 (-0.79%)

05/09/18
LEHM
05/09/18
NO CHANGE
Target $12
LEHM
Underweight
Mallinckrodt price target lowered to $12 from $20 at Barclays
Barclays analyst Douglas Tsao lowered his price target for Mallinckrodt to $12 and keeps an Underweight rating on the shares. While Stannsaporfin was not expected to be a big product commercially, its failure to get the FDA panel vote raises questions on Mallinckrodt's "R&D acumen," Tsao tells investors in a research note. Further, the analyst believes uncertainty on Acthar is likely to persist.
05/04/18
MZHO
05/04/18
NO CHANGE
Target $13
MZHO
Neutral
Mallinckrodt likely to terminate jaundice program, says Mizuho
Mizuho analyst Irina Koffler expects Mallinckrodt to terminate its drug for severe jaundice after an FDA advisory panel recommended against approval. Termination could result in 15c-20c in earnings upside in 2018, Koffler tells investors in a research note. She views the news as a pipeline setback and keeps a Neutral rating on Mallinckrodt.
05/04/18
WELS
05/04/18
NO CHANGE
Target $15
WELS
Market Perform
Mallinckrodt price target lowered to $15 on stannsoporfin news at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Mallinckrodt to $15 from $17.50 after deciding to take stannsoporfin sales out of his model following the joint meeting of the FDA's GI Drugs Advisory Committee and Pediatric Advisory Committee, during which the panel overwhelmingly voted against the approval of stannsoporfin. He spoke with Mallinckrodt after the AdComm and the company said it is "disappointed" with the result and that a path forward for stannsoporfin will be evaluated to see if it makes sense to continue development, Maris noted. He maintains a Market Perform rating on Mallinckrodt shares.
05/02/18
05/02/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alcoa (AA) initiated with a Buy at Jefferies. 2. Spotify (SPOT) initiated with a Buy at SunTrust. 3. Skyworks (SWKS) initiated with an Outperform at Baird. 4. Mallinckrodt (MNK) initiated with a Neutral at B. Riley FBR. 5. CatchMark Timber (CTT) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ABBV AbbVie
$97.58

-1.36 (-1.37%)

06/01/18
PIPR
06/01/18
NO CHANGE
PIPR
Overweight
Piper says Lilly should get some share for Olumiant with aggressive pricing
Piper Jaffray analyst Tyler Van Buren noted that the TNF step-through for Incyte (INCY) and Eli Lilly's (LLY) Olumiant potentially decreases the overall market opportunity, but he believes Olumiant will get some share of TNF failure patients given that Lilly announced it is pricing the drug "aggressively" at a potential 60% price discount to AbbVie's (ABBV) Humira. Van Buren estimates this price to be a potential 50% price discount to the other oral JAK approved for RA, Pfizer's (PFE) Xeljanz. The analyst keeps an Overweight rating on Incyte, citing the durable revenue base through the late 2020s that should come from Olumiant along with the "significant potential" he sees in its pipeline opportunities.
06/11/18
ARGS
06/11/18
NO CHANGE
Target $130
ARGS
Buy
AbbVie price target lowered to $130 from $145 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $130, citing the clinical setback for Rova-T as a treatment for relapsing small cell lung cancer, even though he continues to expect "solid growth" from Humira, Imbruvica, and hepatitis C drugs. Toung also keeps his Buy rating on Abbvie, pointing to the company's "strong product pipeline". The analyst further states that the valuation on AbbVie stock of 11.4-times his expected FY19 EPS is attractive at just below the average industry multiple of 11.9-times given the company's strong growth prospects.
06/01/18
06/01/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Southwest (LUV) downgraded to In-Line from Outperform at Imperial Capital with analyst Michael Derchin saying he expects Southwest to face unit revenue pressures through fiscal 2019 from higher capacity growth in the "weaker" off-peak period as well as heightened competition in California and Denver. 2. AbbVie (ABBV) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying the stock's risk/reward, while once compelling on the reward side, may be skewing increasingly toward risk. 3. Scotts Miracle-Gro (SMG) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the company faces challenges both in its core consumer business and in its hydroponics operation, which serves the cannabis market. 4. Owens Corning (OC) downgraded to Hold from Buy at Argus. 5. Perry Ellis (PERY) downgraded to Market Perform from Outperform at IFS Securities and to Neutral from Buy at Sidoti. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/18
PIPR
06/01/18
DOWNGRADE
Target $105
PIPR
Neutral
AbbVie downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded AbbVie to Neutral and cut his price target for the shares to $105 from $138. The stock closed yesterday down 4%, or $4.07, to $98.94. The stock's risk/reward, while once compelling on the reward side, may be skewing increasingly toward risk, Raymond tells investors in a research note. The analyst thinks investors are underestimating the downside potential from Humira's looming loss of exclusivity in Europe in Q4. And while the U.S. model is very different, another headwind, co-pay accumulators, does not seem to be subsiding, Raymond adds. He thinks it is prudent to step to the sidelines with respect to AbbVie shares.
REGN Regeneron
$308.30

-1.42 (-0.46%)

05/23/18
LEHM
05/23/18
NO CHANGE
Target $290
LEHM
Underweight
Regeneron product concentration remains big risk, says Barclays
Barclays analyst Geoff Meacham says his analysis suggests Eylea concentration remains a big risk for Regeneron Pharmaceuticals (REGN). A scenario analysis shows the company's adjusted earnings is sensitive to even modest changes to U.S. Eylea sales versus any product under the Sanofi (SNY) joint venture, namely Dupixent, Praluent, and Kevzara, Meacham tells investors in a research note. The analyst reiterates an Underweight rating on Regeneron with a $290 price target.
05/08/18
PIPR
05/08/18
NO CHANGE
Target $450
PIPR
Overweight
Piper survey shows 'significant progress' for Regeneron's Dupixent
Piper Jaffray analyst Christopher Raymond says his new survey work indicates "significant progress" for Regeneron Pharmaceuticals' Dupixent both in terms of the drug's quantitative use trends and dermatologists' qualitative views of the drug's commercialization. As such, the analyst believes Dupixent is poised for a "sharp rebound" beginning this quarter, with "significant follow-through" for the remainder of 2018. He maintains above consensus estimates on Dupixent and would be buyers of Regeneron shares on the weakness. Despite the "dismal" year-to-date performance, the stock can "rebound nicely especially on any sign of unexpected commercial traction," Raymond tells investors in a research note. He keeps an Overweight rating on Regeneron with a $450 price target.
05/07/18
RBCM
05/07/18
NO CHANGE
Target $342
RBCM
Sector Perform
Regeneron price target lowered to $342 from $430 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Regeneron to $342 and kept his Sector Perform rating. The analyst says that while Eylea sales exceeded his expectations in Q1, he sees continued pressure for the stock from increasing competition for both Eylea and Dupixent as well as a reimbursement pushback for the latter, reducing his sales expectations on both of these programs.
05/04/18
LEER
05/04/18
NO CHANGE
Target $435
LEER
Outperform
Regeneron price target lowered to $435 from $502 at Leerink
Leerink analyst Geoffrey Porges noted that Regeneron reported mixed Q1 results, stating that Eylea "reassuringly" beat consensus but Dupixent, Kevzara and Praluent fell short of consensus estimates. The big question for Q2 will be the magnitude of recovery in U.S. Dupixent sales, said Porges, who believes better performance for Dupixent, sustained growth in Eylea, growth in Praluent and initial sales of cemiplimab are all essential for Regeneron's stock to recover in the second half of 2018. He maintains an Outperform rating on the stock but lowered his Regeneron price target to $435 from $502.
ALGN Align Technology
$363.62

9.36 (2.64%)

05/24/18
PIPR
05/24/18
NO CHANGE
Target $325
PIPR
Overweight
Align Technology price target raised to $325 from $300 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology to $325 citing yesterday's "positive" investor meeting. The company provided long-term revenue guidance of 20%-30%, above expectations and the previous long-term guidance of 15%-25%), with profitability held steady, O'Brien tells investors in a research note. The analyst is confident that the "key growth drivers are in place from a geographic and product perspective." He continues to view Align as one of the most compelling growth stories in all of med tech and keeps an Overweight rating on the name.
05/24/18
LEER
05/24/18
NO CHANGE
Target $360
LEER
Outperform
Align Technology price target raised to $360 from $305 at Leerink
Leerink analyst Richard Newitter raised his price target for Align Technology to $360 from $305 saying he came away from the company's Analyst Day with increased confidence in the sustainability of its market-leading position in a still-significantly underpenetrated clear aligner/orthodontic market opportunity. The analyst reiterates an Outperform rating on the shares.
05/22/18
STFL
05/22/18
NO CHANGE
Target $350
STFL
Buy
Align Technology price target raised to $350 from $320 at Stifel
Stifel analyst Jonathan Block noted that Align Technology shares have rallied since the AAO meeting and he believes additional upside exists, as investors get more comfortable with Align's future growth despite increasing competition, which may be aided further by the company's analyst day this coming Wednesday. Ahead of that event, where he expects management to provide color on growth, particularly international, and delve deeper into the pipeline, Block raised his price target on Align shares to $350 and keeps a Buy rating on the stock.
05/24/18
JEFF
05/24/18
NO CHANGE
Target $350
JEFF
Buy
Align Technology price target raised to $350 from $300 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Align Technology to $350 saying he left yesterday's investor day more confident in the durability of the company's competitive advantages. Align stands to benefit from the analog to digital shift underway in ortho dentistry, Couillard tells investors in a research note. He keeps a Buy rating on the shares.
SAGE Sage Therapeutics
$169.74

-6.21 (-3.53%)

06/13/18
ADAM
06/13/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics price target raised to $220 from $210 at Canaccord
Canaccord analyst Sumant Kulkarni raised his price target on Sage Therapeutics to $220 from $210 after the company announced it had a positive breakthrough meeting with the FDA on Sage-217, an oral drug being developed for postpartum depression, major depressive disorder and other psychiatric indications. Kulkarni believes the MDD indication is the main stock driver and he views the developments as very encouraging. Kulkarni reiterated his Buy rating on Sage shares.
06/13/18
JEFF
06/13/18
NO CHANGE
Target $9
JEFF
Buy
Sage update yesterday positive for Xenon, says Jefferies
Jefferies analyst Maury Raycroft believes Sage Therapeutics' (SAGE) FDA approval to accelerate a development path for '217 in major depressive disorder and postpartum depression provides a positive read-through for Xenon Pharmaceuticals (XENE). Xenon has two epilepsy programs and one program for hemiplegic migraine, which all have potential in rare disease indications with broader applicability, Raycroft tells investors in a research note. He believes "recent derisking" provides a "great entry point" into Xenon Pharmaceuticals at current share levels. The analyst has a Buy rating on the shares with a $9 price target.
05/03/18
BMOC
05/03/18
NO CHANGE
Target $203
BMOC
Outperform
Sage Therapeutics pipeline programs on track, says BMO Capital
BMO Capital analyst Gary Nachman is pleased with the progress Sage Therapeutics is making building out its commercial infrastructure and preparing for a successful launch of brexanolone. All the company's other pipeline programs remain on track, Nachman tells investors in a post-earnings research note. The analyst remains optimistic in approval with a "very favorable risk/benefit profile." He is an aggressive buyer of Sage shares at current levels and reiterates an Outperform rating on the name with a $203 price target.
06/06/18
LTCO
06/06/18
INITIATION
Target $230
LTCO
Buy
Sage Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Michael Higgins started Sage Therapeutics with a Buy rating and $230 price target.
INSP Inspire Medical
$34.52

1.48 (4.48%)

05/29/18
STFL
05/29/18
INITIATION
Target $42
STFL
Buy
Inspire Medical initiated with a Buy at Stifel
Stifel analyst Jonathan Block started Inspire Medical Systems with a Buy rating and $42 price target, stating that his diligence with ENTs and Sleep Specialists identifies a significant opportunity for the company's Upper Airway Stimulation procedure to gain market share from more invasive surgical procedures. Block also believes the company's clinical data is likely robust enough to eventually win over commercial payors and sets a high hurdle for future competitors, he tells investors.
05/29/18
BOFA
05/29/18
INITIATION
Target $36
BOFA
Neutral
Inspire Medical initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Bob Hopkins initiated Inspire Medical with a Neutral and $36 price target due to valuation.
05/29/18
GUGG
05/29/18
INITIATION
Target $40
GUGG
Buy
Inspire Medical initiated with a Buy at Guggenheim
Guggenheim analyst Chris Pasquale started Inspire Medical with a Buy rating and $40 price target.
05/29/18
GSCO
05/29/18
INITIATION
Target $25
GSCO
Neutral
Inspire Medical initiated with a Neutral at Goldman Sachs
Goldman Sachs started Inspire Medical with a Neutral rating and $25 price target. The firm believes the company's "large" opportunity requires broader reimbursement.
ILMN Illumina
$287.10

-4.96 (-1.70%)

05/16/18
PIPR
05/16/18
NO CHANGE
PIPR
Piper survey shows growth in non-invasive prenatal test volumes
Piper Jaffray analyst William Quirk says his firm's annual survey of obstetricians and gynecologists suggests "significant" near-term growth in average-risk non-invasive prenatal test volume. This is good for Quest Diagnostics (DGX), Illumina (ILMN), LabCorp (LH), Natera (NTRA) and Roche (RHHBY), Quirk tells investors in a research note. Piper found that the number of doctors offering non-invasive prenatal tests to average risk patients increased to 59% in 2018 from 35% last year. Lack of reimbursement remains a barrier to more testing, but importantly, for the second year in a row, resistance to offering NIPT due to Medicaid and clinical data declined, Quirk adds.
05/07/18
05/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McDonald's (MCD) and AutoZone (AZO) were upgraded to Conviction Buy from Buy at Goldman Sachs. 2. Eaton (ETN), Deere (DE), and Terex (TEX) were upgraded to Outperform from In Line at Evercore ISI. 3. LendingTree (TREE) and Santander Consumer (SC) were upgraded to Buy from Neutral at UBS, while Discover (DFS) was upgraded to Neutral from Sell. 4. First Industrial Realty (FR) upgraded to Buy from Neutral at Mizuho with analyst Richard Anderson saying he sees a "path for outperformance from here" with the valuation at "floor" levels. 5. Illumina (ILMN) upgraded to Overweight from Equal Weight at Barclays with analyst Jack Meehan saying he believes his firm's NovaSeq customer survey indicates "substantial elasticity of demand." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/29/18
ADAM
05/29/18
NO CHANGE
Target $290
ADAM
Buy
Illumina price target raised to $290 from $270 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Illumina to $290 from $270 and said it remains a "must-own" large cap stock. The company remains a top pick given its dominant leadership in the next-gen sequencing market. He sees room for raised guidance in 2018 given rising demand for NGS consumables and array consumables/services. Massaro reiterated his Buy rating on Illumina shares.
05/07/18
LEHM
05/07/18
UPGRADE
Target $300
LEHM
Overweight
Illumina upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jack Meehan upgraded Illumina to Overweight and raised his price target for the shares to $300 from $235. The analyst believes his firm's NovaSeq customer survey indicates "substantial elasticity of demand." He sees visibility into "multiple years" of double-digit growth for the company.
JNJ Johnson & Johnson
$122.65

0.11 (0.09%)

06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/05/18
CANT
06/05/18
NO CHANGE
Target $510
CANT
Overweight
Medtronic robot delay 'clear positive' for Intuitive Surgical, says Cantor
Medtronic (MDT) today at its analyst meeting said it expects commercial launch of its surgical robot in fiscal 2020, which is roughly a year delay compared to the company's prior expectations, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note partially titled "ISRG's Headstart Gets Bigger." The analyst views the revised timing of the commercial launch of Medtronic's robot as a "clear positive" for Intuitive Surgical (ISRG). With the commercial launches of the Medtronic and Johnson & Johnson (JNJ) robots at least 18 months away, Intuitive should continue to grow its global installed base, further advancing its global surgical robotics leadership position, Bijou writes. He reiterates his Overweight rating on the shares with a $510 price target. The stock in afternoon trading is up $8.46 to $486.39.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
06/12/18
FBCO
06/12/18
NO CHANGE
Target $151
FBCO
Outperform
Credit Suisse would be surprised to see J&J bid for Boston Scientific
Credit Suisse analyst Vamil Divan would be surprised to see Johnson & Johnson (JNJ) bid for Boston Scientific (BSX), following a report that Stryker (SYK) had approached Boston about a possible acquisition. In general, the analyst believes Johnson & Johnson prefers smaller, targeted acquisitions to larger deals and prefers to obtain technology at an earlier stage before the market has assigned proper value to it. Divan reiterates an Outperform rating and $151 price target on Johnson & Johnson shares.
HUM Humana
$306.15

0.2 (0.07%)

06/01/18
SBSH
06/01/18
INITIATION
Target $340
SBSH
Buy
Humana coverage resumed with a Buy at Citi
Citi analyst Ralph Giacobbe resumed coverage of Humana with a Buy rating and $340 price target. The analyst continues to see the company as well positioned in an "attractive" Medicare Advantage end market that has "broad demographic/structural tailwinds." This creates a solid long-term growth profile for Humana and makes the company a "coveted asset and providing valuation support in the least," Giacobbe tells investors in a research note.
04/16/18
ARGS
04/16/18
NO CHANGE
Target $330
ARGS
Buy
Humana price target raised to $330 from $270 at Argus
Argus analyst David Toung raised his price target on Humana (HUM) to $330 and kept his Buy rating, citing the company's strong Q4 results along with the latest press speculation about acquisition interest from Wal-Mart (WMT). While the merger talks have not been confirmed, the analyst contends that Humana makes for an attractive takeover candidate for Wal-Mart in the wake of recent mergers in the industry, and their partnership would create the "nation's second-largest insurer of Medicare Advantage plans with the nation's largest brick-and-mortar retailer and fourth-largest pharmacy retailer". Toung adds that a strategic partnership would also make sense as it would allow Humana to remain independent and provide Wal-Mart with some insulation as it faces the challenges from Amazon (AMZN) and other online retailers.
04/17/18
LEER
04/17/18
NO CHANGE
LEER
Amazon, Trump news positive for drug supply chain, distributors, says Leerink
Leerink analyst Ana Gupte sees the dual pronged news flow on Amazon (AMZN) being unlikely to enter the Hospital drug supply chain, and President Trump poised to give a speech on drug pricing and supply chain reform on April 26 as HHS Secretary Alex Azar solicits ideas for pricing reform as positive for both the drug supply chain across PBMs and drug distributors and biopharma manufacturers that have been roiled by fears of margin compression on both these threats. Within her coverage, the analyst views this as positive for UnitedHealth (UNH) with its Optum Rx PBM, Cigna (CI) with its deal to acquire Express Scripts (ESRX), and Aetna (AET) which has inked a deal with CVS (CVS) in part through equity, as well as Anthem (ANTM) with IngenioRx and Humana (HUM) with or without its potential Walmart (WMT) deal that has a sizable mail order operation.
05/03/18
OPCO
05/03/18
NO CHANGE
Target $311
OPCO
Outperform
Humana price target raised to $311 from $305 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised his price target for Humana to $311 from $305 following quarterly results. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

LGCY

Legacy Reserves

$4.78

-0.18 (-3.63%)

19:34
09/19/18
09/19
19:34
09/19/18
19:34
Initiation
Legacy Reserves initiated  »

Legacy Reserves initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMT

Core Molding

$7.75

-0.15 (-1.90%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Core Molding names Eric Palomaki VP of Operations »

Core Molding Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMNI

Rimini Street

$6.92

0.33 (5.01%)

19:07
09/19/18
09/19
19:07
09/19/18
19:07
Hot Stocks
Rimini Street obtains Australian single touch payroll certification »

Rimini Street announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$37.30

0.2 (0.54%)

, LCI

Lannett

$4.85

0.15 (3.19%)

18:56
09/19/18
09/19
18:56
09/19/18
18:56
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Herman…

MLHR

Herman Miller

$37.30

0.2 (0.54%)

LCI

Lannett

$4.85

0.15 (3.19%)

AVP

Avon Products

$2.32

0.03 (1.31%)

NGD

New Gold

$1.10

0.03 (2.80%)

AMD

AMD

$31.20

-0.73 (-2.29%)

RHT

Red Hat

$143.38

0.59 (0.41%)

MTEM

Molecular Templates

$6.25

2.15 (52.44%)

CRSP

Crispr Therapeutics

$51.90

-1.27 (-2.39%)

KOS

Kosmos

$9.35

0.04 (0.43%)

VKTX

Viking Therapeutics

$19.64

0.17 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

  • 23

    Sep

  • 27

    Sep

  • 01

    Oct

  • 20

    Sep

  • 21

    Sep

  • 21

    Sep

  • 21

    Sep

LCI

Lannett

$4.85

0.15 (3.19%)

18:49
09/19/18
09/19
18:49
09/19/18
18:49
Hot Stocks
Breaking Hot Stocks news story on Lannett »

MintBroke International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$84.43

-0.86 (-1.01%)

18:43
09/19/18
09/19
18:43
09/19/18
18:43
Periodicals
Nike has sold out 61% more merchandise after Kaepernick ad, Reuters says »

Nike has sold out 61%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 20

    Sep

  • 25

    Sep

ADVM

Adverum Biotechnologies

$5.85

0.05 (0.86%)

18:38
09/19/18
09/19
18:38
09/19/18
18:38
Hot Stocks
Adverum Biotechnologies receives fast track designation for ADVM022 gene therapy »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

BTI

British American Tobacco

$46.87

-0.475 (-1.00%)

18:11
09/19/18
09/19
18:11
09/19/18
18:11
Hot Stocks
British American Tobacco CEO Durante to retire April 1, 2019 »

British American Tobacco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRNY

Kearny Financial

$13.75

0.25 (1.85%)

18:02
09/19/18
09/19
18:02
09/19/18
18:02
Hot Stocks
Kearny Financial declares special cash dividend of 16c per share »

Kearny Financial has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVA

Avista

$51.50

0.01 (0.02%)

18:00
09/19/18
09/19
18:00
09/19/18
18:00
Hot Stocks
Avista, Hydro One extend merger end date »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,926.27

-14.93 (-0.77%)

17:57
09/19/18
09/19
17:57
09/19/18
17:57
Periodicals
Amazon leaks new Alexa smart plug and a subwoofer, Verge says »

According to the Verge,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$163.06

2.75 (1.72%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Periodicals
Facebook sets up 'War Room' for safeguarding elections, NY Times says »

After Facebook gained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

RRTS

Roadrunner

$1.16

-0.065 (-5.33%)

17:45
09/19/18
09/19
17:45
09/19/18
17:45
Syndicate
Roadrunner files S-1 for rights offering to existing holders »

Roadrunner announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$26.45

0.3 (1.15%)

17:35
09/19/18
09/19
17:35
09/19/18
17:35
Hot Stocks
Associated Banc-Corp announces $200M share repurchase program »

Associated's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLIN

Bridgeline Digital

$1.02

-0.01 (-0.98%)

17:32
09/19/18
09/19
17:32
09/19/18
17:32
Syndicate
Breaking Syndicate news story on Bridgeline Digital »

Bridgeline Digital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$1.10

0.03 (2.80%)

17:29
09/19/18
09/19
17:29
09/19/18
17:29
Hot Stocks
New Gold sells Mesquite Mine to Eqiunox Gold for $158M »

New Gold has entered into…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

17:23
09/19/18
09/19
17:23
09/19/18
17:23
Periodicals
Trudeau wants to see more U.S. flexibility around NAFTA, Reuters says »

Canadian prime minister…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$291.22

0.26 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$339.26

-3.94 (-1.15%)

17:18
09/19/18
09/19
17:18
09/19/18
17:18
Hot Stocks
Lockheed Martin awarded $132.3M U.S. Navy contract modification »

Lockheed Martin Rotary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:17
09/19/18
09/19
17:17
09/19/18
17:17
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CFO sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ELAN

Elanco

$0.00

(0.00%)

17:14
09/19/18
09/19
17:14
09/19/18
17:14
Syndicate
Elanco 62.9M share IPO priced at $24.00 »

The IPO priced above its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MAMS

MAM Software

$7.67

0.02 (0.26%)

17:10
09/19/18
09/19
17:10
09/19/18
17:10
Hot Stocks
MAM Software announces $2M share repurchase program »

MAM Software Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:08
09/19/18
09/19
17:08
09/19/18
17:08
Hot Stocks
Coinbase names Brian Brooks chief legal officer »

Coinbase said in a blog…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

FNMA

Fannie Mae

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$143.38

0.59 (0.41%)

17:07
09/19/18
09/19
17:07
09/19/18
17:07
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:06
09/19/18
09/19
17:06
09/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Red Hat »

Red Hat says 24 of its 25…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

RHT

Red Hat

$143.38

0.59 (0.41%)

17:05
09/19/18
09/19
17:05
09/19/18
17:05
Hot Stocks
Red Hat Q2 backlog was up 20% on the year »

Deals over $1M were up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.